A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40193181.
- Also identified by DOI 10.1002/cncr.35838 and PMC identifier 11990110.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This editorial highlights the significant clinical challenges and poor outcomes faced by patients with secondary AML after prior hypomethylating agent therapy (HMA-sAML), underscoring the urgent need for novel treatments. The authors emphasize that current standard therapies remain inadequate, calling for clinical trials tailored specifically to address the unique biological complexity and therapeutic resistance observed in this patient population